News
| 4:44 PM | $CPHD Insider Sale: $2M of stock sold by David Persing (Director Exec Vp,chief Med/tech Officer) on February 7, 2012 http://stks.co/2KvX by MarketBrief |
| 4:42 PM | $CPHD Insider Sale: $1.6M of stock sold between February 7, 2012 - February 8, 2012 http://stks.co/2KvO by MarketBrief |
| 6:03AM | DIARY-U.S. MEETINGS/WEEK AHEAD |
| 12:01AM | Inevitable market pullback postponed |
| Feb 08 | $CPHD a target now? RT @Benzinga Roche Takeover of $ILMN Begins to Fail | http://stks.co/2Itq by tffdo |
| Feb 08 | DIARY-U.S. MEETINGS/WEEK AHEAD |
| Feb 08 | Luminex Has A Lot To Live Up To |
| Feb 07 | $CPHD Insider Sale: $5.8M of stock sold by Humberto Reyes (Executive Vp, Coo) on February 3, 2012 http://stks.co/2IP3 by MarketBrief |
| Feb 07 | $CPHD Insider Sale: $2.7M of stock sold by Andrew Miller (Evp, Cfo) between February 2, 2012 - February 3, 2012 http://stks.co/2IP2 by MarketBrief |
| Feb 07 | $CPHD Insider Sale: $1.7M of stock sold by Nicolaas Arnold (Evp, Worldwide Comm'l Ops) on February 2, 2012 http://stks.co/2IP1 by MarketBrief |
| Feb 07 | Becton Dickinson Too Beloved For Now |
Profile
Exchange: NASDAQGM Sector: Technology Industry: Scientific & Technical Instruments
Cepheid is a broad-based molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for testing in the clinical market, as well as for application in the biothreat, industrial and partner markets. The company's two principal systems are the GeneXpert and SmartCycler. The GeneXpert system integrates sample preparation in addition to DNA amplification and detection. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert Infinity System uses robotic cartridge handling and a full touch screen driven menu, to run up to 1,300 different molecular tests during any 24-hour period, depending upon test selection. The company was founded in 1996 and is based in Sunnyvale, California.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). CEPHEID is up N/A over the last year vs S&P 500 Total Return up N/A, LeCroy Corporation down N/A, and FEI Company up N/A.
- CPHD Total Returns
- ^SPXTR Total Returns
- LCRY Total Returns
- FEIC Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these CPHD related companies
Pro Strategies Featuring CPHD
Did CEPHEID make it into our Pro Portfolio Strategies?
CPHD Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other CPHD Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Quote.com
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CPHD | 42.43 | -0.34 | -0.79% | 2.74B |
| CATM | 26.66 | 0.02 | 0.08% | 1.17B |
| ISIL | 11.40 | -0.06 | -0.52% | 1.45B |
| SNCR | 34.97 | -0.68 | -1.91% | 1.36B |
| SCOR | 22.05 | -0.21 | -0.94% | 709.20M |
| VIVO | 18.03 | -0.18 | -1.02% | 751.19M |
| CHTR | 58.78 | 0.66 | 1.14% | 6.39B |
| IBOC | 19.65 | -0.14 | -0.71% | 1.34B |
| HTLD | 14.95 | -0.03 | -0.20% | 1.31B |
| AINV | 7.04 | -0.07 | -0.98% | 1.40B |
